ATE326469T1 - Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen - Google Patents

Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen

Info

Publication number
ATE326469T1
ATE326469T1 AT02797553T AT02797553T ATE326469T1 AT E326469 T1 ATE326469 T1 AT E326469T1 AT 02797553 T AT02797553 T AT 02797553T AT 02797553 T AT02797553 T AT 02797553T AT E326469 T1 ATE326469 T1 AT E326469T1
Authority
AT
Austria
Prior art keywords
pyrrolopyrimidines
agent
cysteine proteases
inhibiting cysteine
inhibiting
Prior art date
Application number
AT02797553T
Other languages
German (de)
English (en)
Inventor
Claudia Betschart
Kenji Hayakawa
Osamu Irie
Junichi Sakaki
Genji Iwasaki
Rene Lattmann
Martin Missbach
Naoki Teno
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE326469T1 publication Critical patent/ATE326469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02797553T 2001-08-30 2002-08-29 Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen ATE326469T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds

Publications (1)

Publication Number Publication Date
ATE326469T1 true ATE326469T1 (de) 2006-06-15

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797553T ATE326469T1 (de) 2001-08-30 2002-08-29 Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen

Country Status (29)

Country Link
US (2) US7452886B2 (OSRAM)
EP (1) EP1423391B8 (OSRAM)
JP (1) JP4629334B2 (OSRAM)
KR (1) KR100695845B1 (OSRAM)
CN (1) CN100372849C (OSRAM)
AR (1) AR036374A1 (OSRAM)
AT (1) ATE326469T1 (OSRAM)
AU (1) AU2002333760B2 (OSRAM)
BR (1) BR0212226A (OSRAM)
CA (1) CA2458684C (OSRAM)
CY (1) CY1105573T1 (OSRAM)
DE (1) DE60211530T2 (OSRAM)
DK (1) DK1423391T3 (OSRAM)
EC (1) ECSP044998A (OSRAM)
ES (1) ES2262888T3 (OSRAM)
GB (1) GB0121033D0 (OSRAM)
HU (1) HUP0401301A3 (OSRAM)
IL (3) IL160367A0 (OSRAM)
MX (1) MXPA04001935A (OSRAM)
MY (1) MY157368A (OSRAM)
NO (1) NO328890B1 (OSRAM)
NZ (1) NZ531343A (OSRAM)
PE (1) PE20030418A1 (OSRAM)
PL (1) PL368280A1 (OSRAM)
PT (1) PT1423391E (OSRAM)
RU (1) RU2331644C2 (OSRAM)
TW (1) TWI297690B (OSRAM)
WO (1) WO2003020721A1 (OSRAM)
ZA (1) ZA200401042B (OSRAM)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
RU2391094C2 (ru) 2002-09-24 2010-06-10 Новартис Аг Применение агониста рецептора s1p и способ лечения, облегчения или задержки прогрессирования неврита зрительного нерва или демиелинизационных заболеваний
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
WO2004092169A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
AU2004233582B2 (en) * 2003-04-28 2008-05-15 Novartis Ag Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
EP1620421B1 (en) * 2003-04-30 2009-06-24 Bayer CropScience AG Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
UA85576C2 (ru) 2004-02-18 2009-02-10 Астразенека Аб Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
WO2005085210A1 (ja) * 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
CA2564953A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
TW200616968A (en) 2004-08-27 2006-06-01 Ono Pharmaceutical Co Compound having basic substituent and application thereof
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
AU2006277678B2 (en) * 2005-08-05 2012-04-19 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
EA013816B1 (ru) 2005-09-01 2010-08-30 Арес Трейдинг С.А. Лечение неврита зрительного нерва
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
TW200804382A (en) * 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
KR20100090777A (ko) 2007-10-19 2010-08-17 아스트라제네카 아베 대사성 글루타메이트 수용체 (ｍｇｌｕｒ)의 조절제로서의 테트라졸 유도체
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
BR112012016376A2 (pt) 2009-12-30 2019-09-24 Arqule Inc compostos de pirrolo-aminopirimida substituída
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
PT2840083T (pt) * 2012-04-17 2017-11-08 Astellas Pharma Inc Composto heterocíclico aromático bicíclico azotado
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014140933A2 (en) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Method for the prognosis and treatment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
AU2014333513B2 (en) 2013-10-09 2020-11-26 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN107001480B (zh) 2014-12-11 2021-12-03 生物运动有限公司 用于人c-maf的结合成员
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
KR102867720B1 (ko) 2016-05-25 2025-10-01 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
BR112020024427A2 (pt) 2018-06-01 2021-03-23 Incyte Corporation regime de dosagem para o tratamento de distúrbios relacionados a pi3k
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4326721A1 (en) * 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4442687A4 (en) * 2021-12-01 2025-01-22 ST Pharm Co., Ltd. METHOD FOR PREPARING A TRIAZOLOPYRIMIDINONE DERIVATIVE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE609808A (OSRAM) * 1960-11-02
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
ATE247469T1 (de) * 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
EP0970084B1 (en) * 1997-03-19 2003-06-04 Basf Aktiengesellschaft Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors
WO2000000201A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company BICYCLIC sPLA2 INHIBITORS
TR200101186T2 (tr) * 1998-09-18 2001-10-22 Basf Aktiengesellschaft Protein kinaz engelleyiciler olarak pyrrolopyrimidin'ler
CN1195755C (zh) * 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
WO2001070743A1 (en) * 2000-03-20 2001-09-27 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
WO2001083460A1 (en) 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Cyclic compounds

Also Published As

Publication number Publication date
US20090054467A1 (en) 2009-02-26
CN100372849C (zh) 2008-03-05
NO328890B1 (no) 2010-06-07
US20050054851A1 (en) 2005-03-10
MY157368A (en) 2016-06-15
KR20040029123A (ko) 2004-04-03
MXPA04001935A (es) 2004-06-15
KR100695845B1 (ko) 2007-03-20
EP1423391A1 (en) 2004-06-02
DK1423391T3 (da) 2006-09-25
GB0121033D0 (en) 2001-10-24
JP2005502683A (ja) 2005-01-27
WO2003020721A1 (en) 2003-03-13
BR0212226A (pt) 2004-08-17
PE20030418A1 (es) 2003-06-12
PT1423391E (pt) 2006-09-29
ZA200401042B (en) 2004-10-25
EP1423391B1 (en) 2006-05-17
HUP0401301A3 (en) 2008-03-28
EP1423391B8 (en) 2007-12-12
US7452886B2 (en) 2008-11-18
IL198643A (en) 2010-12-30
DE60211530D1 (de) 2006-06-22
AR036374A1 (es) 2004-09-01
CN1549817A (zh) 2004-11-24
AU2002333760B2 (en) 2007-01-04
CA2458684A1 (en) 2003-03-13
ECSP044998A (es) 2004-04-28
RU2004109815A (ru) 2005-10-20
DE60211530T2 (de) 2006-12-21
IL160367A0 (en) 2004-07-25
JP4629334B2 (ja) 2011-02-09
ES2262888T3 (es) 2006-12-01
HK1072254A1 (zh) 2005-08-19
IL160367A (en) 2009-12-24
TWI297690B (en) 2008-06-11
RU2331644C2 (ru) 2008-08-20
NZ531343A (en) 2006-01-27
PL368280A1 (en) 2005-03-21
HUP0401301A2 (hu) 2004-10-28
NO20041180L (no) 2004-03-19
CA2458684C (en) 2009-04-07
CY1105573T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
ATE326469T1 (de) Pyrrolopyrimidine als mittel zur inhibierung von cysteinproteasen
ATE411316T1 (de) Pyrrolopyrimidine als phosphodiesterase-vii- hemmer
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
ATE547412T1 (de) Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
ATE380812T1 (de) Stickstoffhaltige, bicyclische heterocyclen zur verwendung als antibakterielle mittel
ATE393629T1 (de) Verwendung von cci-779 als antineoplastisches mittel
NO20043069L (no) Amfibiekjoretoy
IL210622A0 (en) Compositions and processes for analyte detection
DE60211483D1 (de) Catechine enthaldende getränke
DE60134094D1 (de) C7-taxanester als antitumormittel
NO20042000D0 (no) Fremgangsmate for flerbrukerinnhold
PL370766A1 (en) Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
MXPA03007310A (es) Derivados de ftalazinona piperidino como inhibidores pde4.
DE50204020D1 (de) Mikrotom
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
NO20034452L (no) Sykdoms-assosiert protein
ATE454051T1 (de) Nahrungsmittel enthaltend sättigungsmittel
DE60202489D1 (de) Lysin enthaltende kautablette
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
EP1440733A4 (en) MAGNETIC PARTICLES
DE602004026773D1 (de) Verfahrensherstellung von ethern
ATE369137T1 (de) Lyophilisierte formulierung enthaltend olanzapin
DE60107055D1 (de) Thienopyridinderivate zur verwendung als entzündungshemmende mittel
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DE10290563D2 (de) Mittel zur Hemmung von Tumorzellen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423391

Country of ref document: EP